{
  "api_version": "1",
  "request": {
    "url": "https://clinicaltrialsfind.com/api/v1/search.json?condition=FSGS&page=4",
    "query": {
      "condition": "FSGS",
      "page": 4
    },
    "page_size": 10
  },
  "pagination": {
    "page": 4,
    "page_size": 10,
    "total_count": 78,
    "total_pages": 8,
    "next_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?condition=FSGS&page=5&page_size=10",
    "previous_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?condition=FSGS&page=3&page_size=10"
  },
  "source": "remote",
  "last_synced_at": "2026-10-22T02:30:32.689Z",
  "attribution": "Data derived from public ClinicalTrials.gov records. The official record at https://clinicaltrials.gov/ remains the source of truth for current availability, contacts, and full study details.",
  "notes": [
    "This endpoint exposes only public summary fields — no participant contact emails, phone numbers, or scraped investigator contact details.",
    "For contact information and full protocol detail, follow each trial's `official_url` to the ClinicalTrials.gov record.",
    "This API is a navigational aid. It does not provide medical advice, eligibility determinations, or compensation guarantees."
  ],
  "trials": [
    {
      "nct_id": "NCT07220083",
      "title": "A Study to Find Out if BI 764198 Helps Adults and Adolescents With a Kidney Condition Called Focal Segmental Glomerulosclerosis (FSGS)",
      "overall_status": "RECRUITING",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE3"
      ],
      "conditions": [
        "Focal Segmental Glomerulosclerosis"
      ],
      "interventions": [
        {
          "name": "BI 764198",
          "type": "DRUG"
        },
        {
          "name": "Placebo",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Boehringer Ingelheim",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "12 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "12 Years and older"
      },
      "enrollment_count": 286,
      "start_date": "2026-02-16",
      "completion_date": "2029-01-24",
      "has_results": false,
      "last_update_posted_date": "2026-10-14",
      "last_synced_at": "2026-10-22T02:30:32.689Z",
      "location_count": 77,
      "location_summary": "Alabaster, Alabama • Huntsville, Alabama • Surprise, Arizona + 66 more",
      "locations": [
        {
          "city": "Alabaster",
          "state": "Alabama"
        },
        {
          "city": "Huntsville",
          "state": "Alabama"
        },
        {
          "city": "Surprise",
          "state": "Arizona"
        },
        {
          "city": "Fremont",
          "state": "California"
        },
        {
          "city": "Glendale",
          "state": "California"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT07220083"
    },
    {
      "nct_id": "NCT02000440",
      "title": "A Phase II, Repeat Dose, Proof of Mechanism Study of Losmapimod to Reduce Proteinuria in Patients With Focal Segmental Glomerulosclerosis (FSGS)",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Glomerulosclerosis, Focal Segmental"
      ],
      "interventions": [
        {
          "name": "Losmapimod",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "GlaxoSmithKline",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "70 Years",
        "sex": "ALL",
        "summary": "18 Years to 70 Years"
      },
      "enrollment_count": 17,
      "start_date": "2014-07-01",
      "completion_date": "2016-05-11",
      "has_results": true,
      "last_update_posted_date": "2017-06-12",
      "last_synced_at": "2026-10-22T02:30:32.689Z",
      "location_count": 8,
      "location_summary": "Los Angeles, California • Stanford, California • New Orleans, Louisiana + 5 more",
      "locations": [
        {
          "city": "Los Angeles",
          "state": "California"
        },
        {
          "city": "Stanford",
          "state": "California"
        },
        {
          "city": "New Orleans",
          "state": "Louisiana"
        },
        {
          "city": "Ann Arbor",
          "state": "Michigan"
        },
        {
          "city": "Chapel Hill",
          "state": "North Carolina"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT02000440"
    },
    {
      "nct_id": "NCT03703908",
      "title": "A Study of CCX140-B in Subjects With Primary FSGS and Nephrotic Syndrome",
      "overall_status": "TERMINATED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Focal Segmental Glomerulosclerosis"
      ],
      "interventions": [
        {
          "name": "CCX140-B",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Amgen",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 5,
      "start_date": "2018-10-01",
      "completion_date": "2020-06-24",
      "has_results": true,
      "last_update_posted_date": "2025-03-17",
      "last_synced_at": "2026-10-22T02:30:32.689Z",
      "location_count": 5,
      "location_summary": "Torrance, California • Shreveport, Louisiana • Boston, Massachusetts + 2 more",
      "locations": [
        {
          "city": "Torrance",
          "state": "California"
        },
        {
          "city": "Shreveport",
          "state": "Louisiana"
        },
        {
          "city": "Boston",
          "state": "Massachusetts"
        },
        {
          "city": "Minneapolis",
          "state": "Minnesota"
        },
        {
          "city": "Salt Lake City",
          "state": "Utah"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT03703908"
    },
    {
      "nct_id": "NCT03448692",
      "title": "A Study to Evaluate PF-06730512 in Adults With Focal Segmental Glomerulosclerosis (FSGS)",
      "overall_status": "TERMINATED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Focal Segmental Glomerulosclerosis (FSGS)"
      ],
      "interventions": [
        {
          "name": "PF-06730512",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Pfizer",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 47,
      "start_date": "2018-10-15",
      "completion_date": "2023-02-14",
      "has_results": true,
      "last_update_posted_date": "2024-04-18",
      "last_synced_at": "2026-10-22T02:30:32.689Z",
      "location_count": 56,
      "location_summary": "Birmingham, Alabama • Los Angeles, California • Palo Alto, California + 17 more",
      "locations": [
        {
          "city": "Birmingham",
          "state": "Alabama"
        },
        {
          "city": "Birmingham",
          "state": "Alabama"
        },
        {
          "city": "Birmingham",
          "state": "Alabama"
        },
        {
          "city": "Birmingham",
          "state": "Alabama"
        },
        {
          "city": "Los Angeles",
          "state": "California"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT03448692"
    },
    {
      "nct_id": "NCT05237388",
      "title": "Janus Kinase-STAT Inhibition to Reduce APOL1 Associated Kidney Disease",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Chronic Kidney Diseases"
      ],
      "interventions": [
        {
          "name": "Baricitinib",
          "type": "DRUG"
        },
        {
          "name": "Placebo",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Duke University",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "70 Years",
        "sex": "ALL",
        "summary": "18 Years to 70 Years"
      },
      "enrollment_count": 8,
      "start_date": "2023-04-20",
      "completion_date": "2026-04-03",
      "has_results": false,
      "last_update_posted_date": "2026-04-24",
      "last_synced_at": "2026-10-22T02:30:32.689Z",
      "location_count": 1,
      "location_summary": "Durham, North Carolina",
      "locations": [
        {
          "city": "Durham",
          "state": "North Carolina"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT05237388"
    },
    {
      "nct_id": "NCT05505500",
      "title": "Interview Study of Adult and Child Patients and Parents of Children With Swelling Due to Nephrotic Syndrome.",
      "overall_status": "RECRUITING",
      "study_type": "OBSERVATIONAL",
      "phases": [],
      "conditions": [
        "Fluid Overload",
        "Glomerulosclerosis, Focal Segmental",
        "Edema",
        "Membranous Nephropathy",
        "Minimal Change Disease",
        "Minimal Change Nephrotic Syndrome",
        "IgM Nephropathy",
        "Nephrotic Syndrome",
        "Glomerular Disease",
        "Nephrotic Syndrome, Minimal Change",
        "Nephrotic Syndrome in Children",
        "Nephrotic Syndrome With Edema (Diagnosis)",
        "FSGS"
      ],
      "interventions": [
        {
          "name": "Interview",
          "type": "BEHAVIORAL"
        }
      ],
      "intervention_types": [
        "BEHAVIORAL"
      ],
      "sponsor": "University of Michigan",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "2 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "2 Years and older"
      },
      "enrollment_count": 150,
      "start_date": "2022-04-18",
      "completion_date": "2026-04-30",
      "has_results": false,
      "last_update_posted_date": "2025-12-22",
      "last_synced_at": "2026-10-22T02:30:32.689Z",
      "location_count": 1,
      "location_summary": "Ann Arbor, Michigan",
      "locations": [
        {
          "city": "Ann Arbor",
          "state": "Michigan"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT05505500"
    },
    {
      "nct_id": "NCT05003986",
      "title": "Study of Sparsentan Treatment in Pediatrics With Proteinuric Glomerular Diseases",
      "overall_status": "RECRUITING",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Focal Segmental Glomerulosclerosis",
        "Minimal Change Disease",
        "Immunoglobulin A Nephropathy",
        "IgA Vasculitis",
        "Alport Syndrome"
      ],
      "interventions": [
        {
          "name": "Sparsentan",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Travere Therapeutics, Inc.",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "1 Year",
        "maximum_age": "17 Years",
        "sex": "ALL",
        "summary": "1 Year to 17 Years"
      },
      "enrollment_count": 67,
      "start_date": "2021-08-12",
      "completion_date": "2027-04-12",
      "has_results": false,
      "last_update_posted_date": "2026-05-12",
      "last_synced_at": "2026-10-22T02:30:32.689Z",
      "location_count": 23,
      "location_summary": "Los Angeles, California • Wilmington, Delaware • Miami, Florida + 17 more",
      "locations": [
        {
          "city": "Los Angeles",
          "state": "California"
        },
        {
          "city": "Wilmington",
          "state": "Delaware"
        },
        {
          "city": "Miami",
          "state": "Florida"
        },
        {
          "city": "Miami",
          "state": "Florida"
        },
        {
          "city": "Iowa City",
          "state": "Iowa"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT05003986"
    },
    {
      "nct_id": "NCT01129284",
      "title": "Treatment of Resistant Nephrotic Syndrome With ACTH Gel (ACTHAR)",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE4"
      ],
      "conditions": [
        "Treatment Resistant Nephrotic Syndrome"
      ],
      "interventions": [
        {
          "name": "ACTHAR gel",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Columbia University",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 15,
      "start_date": "2009-12",
      "completion_date": "2011-09",
      "has_results": true,
      "last_update_posted_date": "2014-04-24",
      "last_synced_at": "2026-10-22T02:30:32.689Z",
      "location_count": 1,
      "location_summary": "New York, New York",
      "locations": [
        {
          "city": "New York",
          "state": "New York"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT01129284"
    },
    {
      "nct_id": "NCT00135811",
      "title": "Focal Segmental Glomerulosclerosis Clinical Trial (FSGS-CT)",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE3"
      ],
      "conditions": [
        "Glomerulosclerosis, Focal"
      ],
      "interventions": [
        {
          "name": "Cyclosporin",
          "type": "DRUG"
        },
        {
          "name": "Mycophenolate mofetil and Dexamethasone",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)",
      "sponsor_class": "NIH",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "2 Years",
        "maximum_age": "40 Years",
        "sex": "ALL",
        "summary": "2 Years to 40 Years"
      },
      "enrollment_count": 192,
      "start_date": "2004-11",
      "completion_date": "2009-11",
      "has_results": true,
      "last_update_posted_date": "2026-09-18",
      "last_synced_at": "2026-10-22T02:30:32.689Z",
      "location_count": 1,
      "location_summary": "Cleveland, Ohio",
      "locations": [
        {
          "city": "Cleveland",
          "state": "Ohio"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT00135811"
    },
    {
      "nct_id": "NCT01613118",
      "title": "Randomized, Double-Blind, Safety and Efficacy Study of RE-021 (Sparsentan) in Focal Segmental Glomerulosclerosis",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Focal Segmental Glomerulosclerosis"
      ],
      "interventions": [
        {
          "name": "RE-021 (Sparsentan)",
          "type": "DRUG"
        },
        {
          "name": "Irbesartan",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Travere Therapeutics, Inc.",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "8 Years",
        "maximum_age": "75 Years",
        "sex": "ALL",
        "summary": "8 Years to 75 Years"
      },
      "enrollment_count": 109,
      "start_date": "2014-03",
      "completion_date": "2024-03-25",
      "has_results": true,
      "last_update_posted_date": "2025-05-15",
      "last_synced_at": "2026-10-22T02:30:32.689Z",
      "location_count": 28,
      "location_summary": "San Diego, California • Torrance, California • Denver, Colorado + 19 more",
      "locations": [
        {
          "city": "San Diego",
          "state": "California"
        },
        {
          "city": "Torrance",
          "state": "California"
        },
        {
          "city": "Denver",
          "state": "Colorado"
        },
        {
          "city": "Miami",
          "state": "Florida"
        },
        {
          "city": "Miami",
          "state": "Florida"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT01613118"
    }
  ]
}